A longitudinal study of the cause and consequences of changes in diversification in the U.S. pharmaceutical industry 1977–1986

Strategic Management Journal

Volumn 12, Issue 3, 1991, Pages 187-199

  Hill, Charles W L ^a   Hansen, Gary S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989051475     PISSN: 01432095     EISSN: 10970266     Source Type: Journal    
DOI: 10.1002/smj.4250120303     Document Type: Article

References (29)

1. Diversification strategies, business cycles and economic performance
2. Performance differences in related and unrelated diversified firms
3. Goodness of fit in generalized least squares estimation
4. Corporate economic performance: Diversification strategy versus market structure
5. Industry structure, market rivalry, and public policy
6. The pharmaceutical development process: Estimates of development costs and times and the effects of proposed regulatory changes
7. The industry context of strategy, structure, and performance: The U.K. brewing industry
8. A transaction cost analysis of strategy‐structure choice
9. Research, regulation, and development of new pharmaceuticals: Past, present, and future
10. Product market diversification and market power
11. Diversification strategy, profit performance, and the entropy measure
12. Research on corporate diversification: A synthesis
13. Diversification strategy and profitability
14. Towards an economic theory of the multiproduct firm
15. Returns to research and development in the U.S. pharmaceutical industry
16. Tobin's q and the importance of focus in firm performance